The startup develops single-cell diagnostic tools utilizing deep learning-enhanced 3D holographic imaging for early cancer detection. These tools enable precise therapies aimed at reducing cancer mortality by identifying malignancies at their earliest stages.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer detection methods often lack the sensitivity to identify malignancies at their earliest stages, when treatment is most effective. Traditional diagnostic approaches may also be invasive or lack the resolution to analyze individual cells, hindering precise therapeutic interventions.
Solution
The startup provides single-cell diagnostic tools that leverage deep learning-enhanced 3D holographic imaging for early cancer detection. Their platform enables the visualization and analysis of individual cells in three dimensions, providing detailed morphological information. By applying advanced deep learning algorithms to these high-resolution images, the system can identify subtle cellular changes indicative of early-stage malignancies. This technology facilitates the development of precise, targeted therapies aimed at improving patient outcomes and reducing cancer mortality through early intervention.
Target Audience
The primary target audience includes oncologists, pathologists, and researchers involved in cancer diagnostics and treatment development.
Features
- Deep learning-enhanced 3D holographic imaging for single-cell analysis
- High-resolution visualization of cellular morphology
- Automated detection of early-stage cancer indicators
- Non-invasive diagnostic approach